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Introduction

Micronuclei (MNs) are small nuclear bodies that are formed in
dividing cells but are not part of the nucleus. Therefore, MNs
can only be found in cells that have undergone nuclear division
at least once and appear as small extranuclear bodies. When
two daughter nuclei are formed during cell division, these
bodies are placed into a smaller nucleus that is not part of the
main nuclei, hence the term “micronuclei.”1 Once the MNs are
formed, the cell has several different response options. MNs
can remain within the cell, if they have functional DNA, as
separate entities or be reabsorbed into the main nucleus. If the
DNA is nonfunctional, the MNs may be expelled from the cell
or the whole cell may be destroyed through apoptosis. Because
MNs can be expelled from the cell, they can be used as a mechanism to remove extra chromosomes from the cell.1
MNs can form spontaneously or they can be induced by
mutagens. Some spontaneous MNs are actually beneficial to
the organism. An example is in the mouse cerebral cortex,
wherein MN formation adds diversity to the nervous system.1
However, a large majority of MNs are caused by mutagens
and may play a role in carcinogenesis. Depending on the fate

of the MN, the result could be a variety of different DNA
and chromosome cell contents. This variety could result in
an accumulation of DNA changes and instability that could
result in cancer.1 Several studies have shown that higher MN
counts result in a higher risk of cancer in the future.1 Thus,
using the cytokinesis-block micronucleus (CBMN) assay as
a risk assessment tool for cancer has potential clinical benefits. Further, combining CBMN with other high-throughput
technologies such as gene expression and methylation analyses
may help identify factors related to micronucleation.
Quantifying MNs in patient samples has been shown to
be a good measure of genetic damage. MN scoring, ie, counting the number of MNs present in a sample, is a popular tool
for testing genotoxicity mostly because of its simplicity, accuracy, applicability to different cell types, and ease of automation. Cancer cells show a loss of genetic control, which can be
caused by DNA damage; so, they are good candidates for MN
testing. The CBMN assay has successfully been used and validated to score MNs. The CBMN assay uses cytochalasin-B,
which stops cells from performing cytokinesis but does not
stop nuclear division, giving rise to cells that are binucleated.2,3
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Furthermore, the Organisation for Economic Co-operation
and Development has developed a set of guidelines for running the CBMN assay to obtain the most consistent and reliable results.1
Guidelines for the process of scoring MNs have been
presented by the HUman MicroNucleus (HUMN) project.
This is an international collaborative project aimed at improving the application of the CBMN assay. One of the main goals
of the HUMN project is to identify methodological variables
in the scoring of the assay to minimize confounding effects.4
The HUMN project compiled a list of 6583 subjects from 25
laboratories in 16 countries and looked at background MN
frequency using the CBMN assay. The goal of the study was to
identify variables that affect the background MN frequency.
Scoring criteria were found to account for 47% of the observed
variability; thus, standardized scoring criteria were developed
and described by Fenech et al.4 The guideline includes scoring
2000 cells to accurately estimate MN frequency.
Because these guidelines were developed for assay performance, they do not address how to statistically analyze the data
generated by the assay. This has led to the application of various
statistical methods that may render different interpretations and
conclusions. In a review article examining analytical methods,
Ceppi et al.5 reviewed 63 studies that statistically analyzed MN
data and developed recommendations for selecting an appropriate analytical method. The review included studies that applied
both parametric and nonparametric tests. The nonparametric tests included Kruskal–Wallis, Friedman, Wilcoxon, and
Mann–Whitney U-tests. Although these tests do not require an
underlying distributional assumption, they are unable to adjust
for confounding factors. There were a variety of parametric
tests performed that assume normality, such as analysis of variance, analysis of covariance, and multivariable linear models,
which can adjust for confounding factors. Other methods such
as correlations and Student’s t-test were also used. However,
applying these methods to MN data, which are rarely normally
distributed, could result in inappropriate inferences. Although
the data could be transformed to better adhere to a Gaussian
distribution before applying such parametric tests, few studies
applied any type of transformation. Further, Student’s t-tests
and Pearson’s correlation cannot adjust for confounding variables. The common non-Gaussian models used were log-linear,
Poisson, negative binomial, and logistic regressions. The logistic
and log-linear models account for categories, whereas Poisson
and negative binomial models directly model count data. For
this reason, Ceppi et al.5 recommend using negative binomial
or Poisson models for MN data analysis. Another advantage of
these count models is that they can adjust for confounding variables such as age, gender, and smoking status. Finally, Ceppi
et al.5 recommended that 2000 or more cells be scored for best
model performance. If ,2000 cells are scored, a zero-inflated
Poisson model is recommended.5
When trying to identify molecular features related to
MN frequency, high-throughput genomic assays can be used.
98
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However, the previously described methods cannot be applied
in settings wherein there are more predictor variables than
samples. Therefore, in this study, we extended the generalized
monotone incremental forward stagewise (GMIFS) method
to the Poisson regression setting and applied it to a cord blood
study, the MN frequency of which we were interested in predicting using features from the Agilent 4 × 44k human oligonucleotide microarray.

Methods

Data. The cord blood data were collected as part of the
Norwegian Mother and Child Cohort Study (MoBa).6 The
target population of MoBa comprised all women who gave
birth in Norway. The overall goal of this study was to collect
data on pregnant women and their children to estimate the
association between exposures and diseases. Specifically, the
data are taken from a subcohort called BraMat, which translates to “good food” in English. This subcohort concentrates on
what effect a pregnant woman’s diet has on her child. Umbilical cord blood samples were collected immediately after birth
from 200 babies. After quality control and other exclusions,
111 samples were hybridized to Agilent 4 × 44k human oligonucleotide microarrays to measure gene expression. Of the
111 subjects, 29 also had MN data collected. The MNs were
scored using the procedure described by Decordier et al.7 Further, demographics such as gender, were collected for all subjects. Data were downloaded from Gene Expression Omnibus
(GSE31836). Sample processing, image analysis, normalization, background correction, and filtering are described in the
study by Hochstenbach et al.8 For this analysis, the data were
further filtered to only include genes that had no missing values, leaving 8497 genes for statistical analysis.
Statistical methods. There are many available methods
that can model count data. However, these methods require
independence of explanatory variables (p) and that the number of
samples (n) does not exceed the number of explanatory variables.
The incremental forward stagewise regression method for linear
regression and the GMIFS for a logistic regression model have
been previously described.9 The GMIFS method for modeling
ordinal response data has also been described.10 To assist in our
extension to the Poisson regression setting, we first review Poisson regression. We subsequently describe our GMIFS method
for fitting Poisson regression models when n , p.
Poisson regression. Poisson regression is commonly used
to model count data. Let i = 1,…, n be the number of observations and yi represent a Poisson-distributed random variable.
Let the expected value of yi be written as

( )

E yi = λ i .
Then, the conditional probability is given by

(

)

P yi | λ i =

e − λi λ iyi
yi !
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for each observation i. The likelihood is represented by
n

L (λ | y ) = ∏

e − λi λ iyi

i =1

yi !

.

Mathematically, it is easier to maximize the log-likelihood,
which is given by
n

(

( ))

 ( λ | y ) = ∑ yi log λ i − λ i − log yi ! .
i =1

Thus, we are looking for the value of λ that maximizes the
log-likelihood above. Further, an offset is used if the response
variable can be considered a rate. For example, MN frequency
is scored from a larger number of total cells. Therefore, if the
total number of cells examined varies by subject, an offset is
appropriate. In this case, the expected value is

( )

E yi = t i λ i
where ti is the offset value. The conditional probability is then
given by

(

)

P yi | λ i =

( )

e − ti λ i t i λ i

yi

yi !

for each observation i. The likelihood is represented by
n

L (λ | y ) = ∏

( )

e − ti λ i t i λ i

i =1

yi !

yi

.

Again, mathematically, it is easier to maximize the loglikelihood, which is given by
n

(

( )

and taking the exponent, we can calculate the estimated
response of that particular subject.
GMIFS Poisson model. The GMIFS method was previously described for the logistic regression scenario by Hastie
et al.9 but can be adapted to a Poisson regression model. For the
proposed method, we consider three types of parameters that
θ from the section “Poisson regression” can be separated into
along with an offset (ti). The parameters are the intercept (α),
those corresponding to an unpenalized subset of predictors (γ),
and those corresponding to a set of penalized predictors (β). The
design matrix, x, consists of two parts, xj and xk, where j = 1,…, J
is the number of unpenalized predictors, k = 1,…, K is the set of
penalized predictors, and J + K = P is the total number of predictors. The unpenalized predictors are those that we wish to force
into the model, such as gender, age, and smoking status, which
researchers consider important predictors of MN frequency5 and
their values are in the xij design matrix for subject i. The penalized variables (thousands of features from a high-throughput
genomic experiment) are those that the model will choose for
us and are considered to be the investigative predictors and their
values are in the xik design matrix for subject i.
The algorithm proceeds in an iterative fashion and updates
one of the penalized covariates by a small incremental amount
at each step. To determine which penalized covariate is to be
updated next, the largest negative gradient is used. Thus, we
need to calculate the first derivative of the log-likelihood corresponding to each penalized predictor. The log-likelihood
written in terms of α, β, and γ is

and the first derivative written in terms of α, β, and γ in matrix
notation is

( ))

 ( λ | y ) = ∑ yi log ti λ i − ti λ i − log yi ! .
i =1

Once again, we are looking for the λ value that maximizes
the log-likelihood. These log-likelihoods are used to model
predictor variables. In Poisson regression, the model assumes
that the expected value can be modeled by a linear combination of predictors. In this case, the natural log of ti is entered
as an offset in the model estimation. The natural log of the
expected value is

where xi is a vector of predictor variables and θ is a vector of
coefficients. The estimated coefficients can be exponentiated
to determine how the response changes with the predictor. By
using the estimated linear combination of coefficient estimates

Once we know which covariate to update, we need to
determine in what direction to update the covariate. To know
the direction of the update, the second derivative would need
to be calculated, which is a cumbersome process. Hastie et al.9
showed that to avoid having to calculate the second derivative, an expanded covariate space can be used. For example, let
β1,…, βp be the positive coefficient estimates and βp+1,…, β2p
be the negative coefficient estimates. Then, the original estimates are calculated by subtracting the pairs, β1 – βp+1,…,
β2p – β2 . Thus, using the notation mentioned previously,
where xj are the unpenalized variables and x k are the variables in the penalized subset, the expanded covariate space is
x =  x j : x k : − x k . The proposed GMIFS algorithm using the


expanded covariate set is
CANCER INFORMATICS 2015:14(S2)
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1.
2.
3.

4.
5.
6.

Initialize the components of
at step s = 0.
Initialize the intercept α and the unpenalized coefficients
γj where j = 1,…, J using a maximization algorithm of the
log-likelihood.
Considering α and γ fixed, find the predictor xm where
 ∂l 
m = argmin  −
.
 at the current estimate
K
 ∂β k 
s
s
1
+
(
)
( )
Update the corresponding coefficient βm = βm + ε to
yield a new vector of parameter estimates.
Update α and the unpenalized coefficients, γj, by maximum likelihood considering the
from step 4 as
fixed.
Repeat steps 3–5 until the difference between successive
log-likelihoods is less than a prespecified tolerance, τ.

The defaults for the GMIFS algorithm are ε = 0.001 and
τ = 0.00001.
Comparative method: penalized linear regression.
A penalized linear regression model can be fit by adding a
penalty term to the sums of squares. Specifically, the glmpath
algorithm uses a linear combination of the L1 and L2 norm
penalizations. The generalized linear model path (glmpath)
algorithm is based on a previous algorithm called least absolute
shrinkage and selection operator (LASSO). LASSO mini
mizes the typical sum of squares with an added constraint.
Specifically, for linear regression, LASSO minimizes11
2

p


∑  yi − ∑ xij β j  + λ ∑ | β j |
i =1
j
j =1
N

where xij are the standardized predictors and yi is the set of
centered responses for i = 1,…, N and j = 1,…,p. Because of the
form of the constraint, LASSO does both variable selection
and shrinkage. The glmpath algorithm modifies this slightly
by first considering the typical generalized linear model
formula

where L denotes the appropriate likelihood function. The
glmpath algorithm then adds an analagous LASSO penalty
term to help with variable selection when p . n:

where λ . 0 is the regularization parameter. The glmpath
algorithm computes coefficient estimates as λ varies. The
algorithm starts with the largest λ that makes β (λ ) nonzero,
with each step using a smaller λ. Each optimization consists
of three parts: determining the step size in λ, predicting the
100
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corresponding change in the coefficients, and correcting the
error in the previous prediction.12 The algorithm continues
finding the next largest λ that will change the coefficient
estimates until no further predictors can be found. However,
when the predictors are strongly correlated, the coefficient
estimates become highly unstable using the L1 norm penalization.9 Thus, the glmpath algorithm adds a quadratic penalty
term and computes the solution to

	 
where λ1 ∈ (0, ∞) and λ2 is a fixed, small, positive constant.
By adding this quadratic penalty, the effects of the strong correlations do not affect the stability of the fit. Further, when the
correlations are not strong, the effects of the quadratic penalty
are neglible.9 Thus, the glmpath algorithm uses both the L1
and L2 penalties as its default method.
The glmpath algorithm uses a default binomial distribution with a logit link and λ2 = 0.00001. The algorithm also
allows for a Poisson distribution with a log link and Gaussian
distribution with an identity link. The algorithm then computes the regularization path for generalized linear models
with L1 penalty.
Simulations. Simulations are a useful technique to test
how well a new methodology performs. In this case, we wished
to quantify how accurately the GMIFS method estimated true
nonzero coefficients and predicted count data. Furthermore,
we wished to determine how the GMIFS method compared
relative to the glmpath method in predicting the count outcome, and simulations provide a good platform to accomplish
this comparison. Several general steps must be considered in
the simulation process: how to simulate the response, how to
simulate the predictors associated with the response, and how
to simulate the predictors not associated with the response.
Furthermore, we wished to examine how the methods perform under ideal situations and nonideal situations, such as
when distributional assumptions are met and are not met,
respectively. Note that all simulations were performed using
the R programming environment (version 3.1.1).13
First, we considered the situation where the response
is Poisson distributed and the user fits a Poisson regression
model. Then, we generated the response to follow a Poisson
distribution where an offset was either used or not used. The
uniform distribution was used to generate the predictors. The
steps involved in simulating the data under these conditions
were as follows:
1.
2.

Randomly generate P variables, xi1, xi2,…, xiP where
i = 1…n, using the uniform distribution on the [0,1]
interval.
Choose P 1 of the P variables to be associated with the
response.

GMIFS poisson model for modeling count data

3.

4.

Assign the P 1 β values associated with the response and
the intercept value, α. If the offset is to vary, then a uniform distribution was used with maximum 2200 and
minimum 1800 and subsequently rounded to the nearest integer. This range was selected because it is recommended to score MNs using 2000 cells.
Generate the λ values for the Poisson distribution using
the following formula:
P1


λi = exp  α + log ti + ∑ βk x ik  .


k =1

( )

5.
6.
7.

Randomly generate Yi ∼ Poisson(λi).
Fit a Poisson GMIFS model and fit a glmpath model.
Repeat steps 1–6 r times.

This simulation method was adjusted in several places.
In this case, we chose n = 30 and n = 80. We studied the
models letting P = 100 predictor variables and P 1 = 5 predictor variables associated with the response; r = 100 simulations
were used. The intercept (α) and the five predictor variables
associated with the response (β1, β2, β3, β4, and β5) were set to
–5, 0.3, 0.2, –0.7, 0.5, and 0.1, respectively, for data simulated
using no offset. For data simulated using an offset, α was set
to –7. This was done to keep λ values low so that the Gaussian
approximation for the Poisson distribution is not appropriate.
To compare the two different statistical models, the following
three outcomes were examined:
1.
2.
3.

The number of true predictors that have a nonzero
coefficient;
the number of false predictors that have a nonzero
coefficient;
accuracy of count predictions from the model (sum of
squared residuals) when applied to an independent test
set.

The methods were compared with and without the use
of an offset during the simulation process. Furthermore, the
glmpath method allows for the use of Gaussian and Poisson
distributions. Thus, those options were also used to see what
effects user error had on the results. Thus, a total of three models were compared when the true distribution was Poisson:
1.
2.
3.

Poisson GMIFS model;
glmpath using “poisson” family option and λ2 = 0 which
fits a LASSO model; and
glmpath using “gaussian” family option and λ2 = 0 which
fits a LASSO model.

Results

Simulations. Simulations were performed as described in
“Simulations” of the Methods section, and Figures 1–3 show

the results of the simulations. Figure 1 shows the distribution
of the number of predictors correctly identified as nonzero
over 100 simulations and the types of models used. The data
were generated using both n = 30 and n = 80 observations. The
median number of correctly identified nonzero coefficients
with no offset using GMIFS is 1 (range = 0, 3) for n = 30 and
2 (range = 0, 4) for n = 80. Similarly, the median number of
correctly identified nonzero coefficients with no offset using
glmpath with Poisson family is 1 (range = 0, 5) for n = 30 and
2 (range = 0, 4) for n = 80. This number increases slightly
when using the glmpath with Gaussian family to a median
of 2 (range = 0, 5) for n = 30 and 4 (range = 2, 5) for n = 80.
All the numbers are similar when an offset is used to generate
the data. The median number of correctly identified non-zero
coefficients using GMIFS is 0 (range = 0, 3) for n = 30 and
1 (range = 0, 4) for n = 80. The median number of correctly
identified non-zero coefficients using glmpath with Poisson
family is 0 (range = 0, 3) for n = 30 and 1 (range = 0, 4) for
n = 80. Once again the medians increase when using the glmpath with Gaussian family to 2 (range = 0, 5) for n = 30 and 4
(range = 2, 5) for n = 80.
Figure 2 shows the distribution of the number of predictors incorrectly identified as nonzero over 100 simulations
and the types of models used. The data were generated using
both n = 30 and n = 80 observations. The median number of
incorrectly identified nonzero coefficients with no offset using
GMIFS is 3 (range = 0, 15) for n = 30 and 7 (range = 0, 28) for
n = 80. Similarly, the median number of incorrectly identified
nonzero coefficients with no offset using glmpath with Poisson family is 3 (range = 0, 17) for n = 30 and 7 (range = 0, 41)
for n = 80. This number increases when using the glmpath
with Gaussian family to a median of 26 (range = 23, 28) for
n = 30 and 74 (range = 73, 76) for n = 80. All results are similar when an offset is used to generate the data. The median
number of incorrectly identified non-zero coefficients using
GMIFS is 2 (range = 0, 14) for n = 30 and 5 (range = 0, 26) for
n = 80. The median number of incorrectly identified non-zero
coefficients using glmpath with Poisson family is 2 (range = 0,
24) for n = 30 and 4.5 (range = 0, 31) for n = 80. Once again
the medians increase when using the glmpath with Gaussian
family to 26 (range = 23, 28) for n = 30 and 74 (range = 72,
76) for n = 80.
Figure 3 shows the distribution of the sum of residuals
squared as a measure of the model prediction accuracy. The
data were generated using both n = 30 and n = 80 observations. For both sample sizes, a learning data set was used to
estimate coefficients and then the model was applied to an
independent test data set. The median accuracy with no offset
using GMIFS is 133 (range = 68, 240) for n = 30 and 325
(range = 188, 699) for n = 80. Similarly, the median accuracy with no offset using glmpath with Poisson family is 142
(range = 55, 254) for n = 30 and 333 (range = 185, 1666) for
n = 80. The median accuracy with no offset using glmpath
with Gaussian family is 206 (range = 90, 383) for n = 30 and
CANCER INFORMATICS 2015:14(S2)
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Number predictors correctly
identified as non-zero

7
No offset n = 30
No offset n = 80
Offset n = 30
Offset n = 80

6
5
4
3
2
1

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

0

Figure 1. Number of predictors correctly identified as nonzero. This figure shows the distribution of the number of predictors correctly identified as
nonzero over 100 simulations. There were five predictors that were set as nonzero. Boxplots are separated by the type of distribution used to generate
the data and the number of observations.

1503 (range = 535, 3772) for n = 80. The numbers are different
when an offset is used to generate the data. The median accuracy using GMIFS is 80 (range = 30, 185) for n = 30 and 205
(range = 137, 367) for n = 80. The median accuracy using glmpath with Poisson family is 80 (range = 33, 805) for n = 30 and
206 (range = 126, 339) for n = 80. The median accuracy with
an offset using glmpath with Gaussian family for both sample
sizes is above 50000.

Gene expression analysis. Both GMIFS and glmpath
models were applied to the cord blood gene expression data set
described under “Data” of Methods section. For glmpath, the
Poisson family option was used and the lambda2 option was
set to zero. For GMIFS, the default options were chosen. The
response in the model was MN counts, and the predictors were
the gene expression intensities. Gender was included in the
model as part of the unpenalized subset. Based on Figure 4, a

No offset n = 30
No offset n = 80
Offset n = 30
Offset n = 80

80

60

40

20

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

GMIFS

glmpath
Gaussian

0

0

glmpath

Number predictors incorrectly
identified as non-zero

100

Figure 2. Number of predictors incorrectly identified as nonzero. This figure shows the distribution of the number of predictors incorrectly identified as
nonzero over 100 simulations. There were 95 predictors for which their coefficients were set to zero. Boxplots are separated by the type of distribution
used to generate the data and the number of observations.
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Sum of squared residuals

4000

No offset n = 30
No offset n = 80
Offset n = 30
Offset n = 80

3000

2000

1000

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

glmpath
Gaussian

glmpath

GMIFS

0

Figure 3. Accuracy of count predictions. This figure shows the distribution of the sum of residuals squared over 100 simulations using a learning
data set and an independent test data set. Boxplots are separated by the type of model fit to the data and the number of observations. The results for
glmpath with Gaussian family using an offset are not displayed because both values are above 50000.

Poisson distribution was assumed for both models because the
data appear skewed. The final model parameters were chosen
using the minimum Akaike information criterion. The GMIFS
model identified 17 nonzero gene expression coefficients as
associated with MN count and the glmpath with Poisson family identified 23. Out of the genes that were identified, 10 were
common to both models. Figures 5 (sum of squared residuals = 101.7) and 6 (sum of squared residuals = 1.8) show that
both models seem to predict MNs relatively well. Table 1 shows
the genes that both models identified as being associated with
MN count and the types of cancer with which they are linked.
Nine out of the 10 genes in common between both models are
linked to some type of cancer.

Discussion

We have described the GMIFS method for modeling a count
response when we want to (1) coerce some variables into the

model and (2) perform automatic variable selection and model
estimation by penalizing predictors. High-throughput data
contain more predictors than there are samples, so traditional
methods are not appropriate in this setting. The GMIFS
method was compared to glmpath, a popular penalization
algorithm. Simulations showed that both methods performed
similarly when identifying predictors known to be nonzero.
GMIFS appeared to slightly outperform glmpath in the sense
that GMIFS included fewer predictors that are truly unimportant in the model. Similarly, when applied to an independent data set, GMIFS appeared to have higher predictive
accuracy. Thus, it appears that GMIFS is more generalizable
than glmpath to independent data sets.
Finally, both methods were applied to a cord blood
gene expression data set. Gene expression profiles were used
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Figure 5. Plot of actual MN counts versus predicted MN counts using
GMIFS.
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Table 1. Genes identified as associated with MN count by both GMIFS and glmpath.
PROBE ID

GENE SYMBOL

GENE NAME

ASSOCIATED WITH CANCER

GMIFS

GLMPATH

A-23-P100196

USP10

ubiquitin specific peptidase 10

Glioblastoma multiforme14

X

X

A-23-P138967

SDHD

succinate dehydrogenase complex

Tumor Suppressor15

X

X

A-23-P42331

HMGA1

high mobility group AT-hook 1

Pancreatic Adenocarcinoma16

X

X

A-23-P9293

TJP2

tight junction protein 2

Breast

X

X

A-24-P19410

CBX7

chromobox homolog 7

Carcinomas18

X

X

A-24-P214858

TREML2

triggering receptor expressed on
myeloid cells-like 2

Pancreatic

X

X

A-24-P2463

WHSC1

Wolf-Hirschhorn syndrome candidate 1

Carcinogenesis20

X

X

A-24-P397584

TBCC

tubulin folding cofactor C

None Found

X

X

A-24-P398064

KIAA0258

KIAA0258

Colorectal21

X

X

A-32-P18547

C21ORF57

chromosome 21 open reading frame 57

Breast

X

X

A-23-P103824

FAU

Finkel-Biskis-Reilly murine sarcoma
virus (FBR-MuSV) ubiquitously expressed

None Found

X

A-23-P209394

CFLAR

CASP8 and FADD-like apoptosis regulator

Human cancers23

X

A-23-P79911

PSMF1

proteasome (prosome, macropain) inhibitor
subunit 1 (PI31)

Breast

X

A-24-P202567

ITPKC

inositol 1,4,5-trisphosphate 3-kinase C

Cervical25

A-24-P31235

EIF5A

eukaryotic translation initiation factor 5A

Chronic myeloid leukemia

A-24-P405054

C1ORF144

chromosome 1 open reading frame 144

Mantle cell lymphoma27

A-32-P156549

C1ORF144

A-23-P118313

GABARAPL2

GABA(A) receptor-associated protein-like 2

Lung28

A-23-P143817

MYLK

myosin, light polypeptide kinase

Gastric

A-23-P156809

LOC642880

similar to FKSG62

None Found

X

A-23-P394304

PDZK1IP1

PDZK1 interacting protein 1

Thyroid30

X

A-23-P39665

SLC11A1

solute carrier family 11, member 1

Esophageal

A-23-P67529

KCNN4

potassium intermediate/small conductance
calcium-activated channel, subfamily N,
member 4

Colorectal32

A-24-P594683

LOC645592

similar to peptidylprolyl isomerase
A isoform 1

GNA12

guanine nucleotide binding protein
(G protein) alpha 12

17

19

22

24

X
X
X
X

29

31

X
X

X
X
Oral33

X

A-32-P10067

X

A-32-P137849

X

A-32-P169754

LOC145221

EST

A-32-P208078

MTHFR

5,10-methylenetetrahydrofolate reductase
(NADPH)

to predict MN frequency. Both models identified a similar
number of genes as related to MN frequency. Further, 10 of
those genes were common to both models. Nine out of the
10 genes have been shown to be associated with different types
of cancers. Because MN count is a measure of DNA damage,
genes associated with MN frequency would be expected to be
linked to cancer.
Both models appear to identify genes linked to cancer. As
in the simulations, glmpath identified more genes as nonzero
compared to GMIFS. In the simulations, this was because glmpath was including more predictors incorrectly. However, there
104

X
X

A-24-P708161
A-24-P98086

26
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X
Breast

34

X

is no way to know whether this is also the case in the cord blood
data set, given that these data are observational and no further
confirmatory studies can be performed on the samples.
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